Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.

Slides:



Advertisements
Similar presentations
MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
Advertisements

CABG VS Multi Vessel PCI Hasanat Sharif MD FRCS Chief of Cardiorthoracic Surgery Aga Khan University Hospital.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
ARTS I & II Keith D Dawkins Southampton University Hospital.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
PCI VS CABG JOURNAL REVIEW
CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Lesson 4 What is the treatment for Coronary Artery Disease?
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Journal Club: Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease Tiffany Sun, MD May 19, 2009.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Coronary Artery Disease in Diabetic Patients, Different from Non-diabetics?
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.
Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Multivessel Coronary Artery Disease
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.
Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.
The project described herein is supported by Award Number RC2HL from the National Heart, Lung, and Blood Institute The content is solely the responsibility.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Copyright © 2014 American Medical Association. All rights reserved.
From: Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery Ann Intern Med.
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Figure 1 A flow chart describing the systematic process followed for article selection.  From: A systematic review of cost-effectiveness of percutaneous.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
SYNTAX at 2 Years: This Interventionalist’s Perspective
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
Percutaneous coronary invervention versus coronary artery bypass grafting: A meta- analysis  Yolba Smit, MD, MSc, Joan Vlayen, MD, Hetty Koppenaal, MD,
Nat. Rev. Cardiol. doi: /nrcardio
J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Three-Year Outcomes of Multivessel Revascularization in Very Elderly Acute Coronary Syndrome Patients  Brett C. Sheridan, MD, Sally C. Stearns, PhD, Joseph.
Why surgery won the SYNTAX trial and why it matters
Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris  Toshihiro Fukui,
Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p
LRC-CPPT and MRFIT Content Points:
Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease  Robert.
Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD 
Long-Term Survival After Coronary Arterial Grafts in Patients With End-Stage Renal Disease  Taro Nakatsu, MD, Nobushige Tamura, MD, PhD, Yutaka Sakakibara,
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact  Jack V. Tu, MD, PhD, Anam M. Khan,
Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.
(A) Meta-analysis of repeat revascularisation in randomised trials.
Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease  Tetsuro Tsujimoto, Hiroshi Kajio 
To bypass or stent? The changing rules of an advancing game
Revascularization Strategies and Survival in Patients With Multivessel Coronary Artery Disease  Noam Fink, MD, Eugenia Nikolsky, MD, Abid Assali, MD,
Stent Versus Off-Pump Coronary Bypass Grafting in the Second-Generation Drug- Eluting Stent Era  Gijong Yi, MD, PhD, Hyun-Chel Joo, MD, Young-Nam Youn,
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
Glenn N. Levine et al. JACC 2011;58:e44-e122
Leslee J. Shaw et al. JIMG 2010;3:
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
Improved Long-Term Survival for Diabetic Patients With Surgical Versus Interventional Revascularization  Paul Kurlansky, MD, Morley Herbert, PhD, Syma.
Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test
Presentation transcript:

Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015

CABG: The Gold Standard Coronary Artery Bypass Grafting (CABG) has been THE MOST STUDIED and scrutinized procedure in the history of medicine. Why? Rates of CABG declining substantially locally and nationally. Why? What is role of CABG in age of Percutaneous Coronary Intervention (PCI)? BMS and DES

CABG: The Gold Standard  No longer most common operation for Cardiac Surgeon  Current Role of Cardiology as “Gatekeeper”  Patient Preference?  Current CABG candidates – in general, those who can’t have PCI  Evidenced based Medicine??

CABG: The Gold Standard Randomized Trials (RCT) and Registries: CABG vs PCI: Acronyms Galore, BMS, DES, etc Outcomes: Mortality, Stroke, Re-intervention Rates and Myocardial Infarction Weaknesses of RCT’s: Atypical populations, small numbers of patients, Crossovers, and short duration of follow-up

CABG: The Gold Standard Registries: Large number of patients, propensity matched, represent “real world” conditions, but fatal flaw is treatment bias

CABG: The Gold Standard 3 important clinical Trials: SYNTAX, FREEDOM, and ASCERT SYNTAX: (NEJM 2005)  Landmark trial  “all comers”  5 year outcomes  Absolute decrease in mortality, cardiac death, myocardial infarction, and need for repeat revascularization in CABG group  Survival curves for PCI and CABG continuing to diverge

CABG: The Gold Standard FREEDOM (NEJM 2012): Multivessel disease with Diabetes Superiority of CABG demonstrated again with absolute increase in survival rate and decreased rate of Myocardial infarction

CABG: The Gold Standard FUNDAMENTAL QUESTION WHY DOES CABG HAVE A SURVIVAL BENEFIT OVER PCI?

CABG: The Gold Standard  Anatomically, atheroma is located in the proximal portion of the coronary arteries.  CABG places grafts to the mid portion of the vessels, giving benefit against the recurrence of the culprit lesion and development of future atheroma  Future PCI strategies unlikely to approach the benefits of CABG in complex CAD

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.